Shares of Molina Healthcare, Inc. (NYSE:MOH - Get Free Report) have been assigned a consensus rating of "Hold" from the fifteen ratings firms that are presently covering the firm, MarketBeat.com reports. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $365.38.
MOH has been the topic of a number of analyst reports. Guggenheim assumed coverage on Molina Healthcare in a research note on Wednesday, April 9th. They issued a "neutral" rating on the stock. Stephens reaffirmed an "equal weight" rating and set a $345.00 price objective on shares of Molina Healthcare in a research note on Thursday, February 6th. Robert W. Baird reaffirmed a "neutral" rating and set a $375.00 price objective (up previously from $331.00) on shares of Molina Healthcare in a research note on Tuesday, April 15th. UBS Group dropped their price objective on Molina Healthcare from $374.00 to $325.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Finally, Truist Financial raised their price objective on Molina Healthcare from $340.00 to $400.00 and gave the stock a "buy" rating in a research note on Friday, April 11th.
Check Out Our Latest Analysis on Molina Healthcare
Insiders Place Their Bets
In other news, Director Richard M. Schapiro sold 669 shares of the firm's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $320.50, for a total value of $214,414.50. Following the completion of the transaction, the director now owns 11,244 shares in the company, valued at $3,603,702. This trade represents a 5.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joseph M. Zubretsky sold 87,500 shares of the firm's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $320.06, for a total value of $28,005,250.00. Following the completion of the transaction, the chief executive officer now owns 257,715 shares of the company's stock, valued at $82,484,262.90. The trade was a 25.35% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 89,169 shares of company stock worth $28,520,995. Corporate insiders own 1.10% of the company's stock.
Hedge Funds Weigh In On Molina Healthcare
Several hedge funds have recently modified their holdings of the stock. Rothschild Investment LLC grew its holdings in Molina Healthcare by 126.3% during the first quarter. Rothschild Investment LLC now owns 86 shares of the company's stock worth $28,000 after purchasing an additional 48 shares during the period. Zions Bancorporation National Association UT bought a new position in Molina Healthcare during the first quarter worth about $29,000. Colonial Trust Co SC grew its holdings in Molina Healthcare by 930.0% during the fourth quarter. Colonial Trust Co SC now owns 103 shares of the company's stock worth $30,000 after purchasing an additional 93 shares during the period. Deseret Mutual Benefit Administrators grew its holdings in Molina Healthcare by 60.7% during the first quarter. Deseret Mutual Benefit Administrators now owns 90 shares of the company's stock worth $30,000 after purchasing an additional 34 shares during the period. Finally, Elequin Capital LP grew its holdings in Molina Healthcare by 170.6% during the first quarter. Elequin Capital LP now owns 92 shares of the company's stock worth $30,000 after purchasing an additional 58 shares during the period. Institutional investors own 98.50% of the company's stock.
Molina Healthcare Trading Up 0.8%
Shares of MOH stock traded up $2.57 during trading hours on Friday, reaching $307.80. The company had a trading volume of 423,812 shares, compared to its average volume of 692,698. The company has a 50 day moving average of $324.25 and a 200 day moving average of $307.58. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.62 and a quick ratio of 1.62. The firm has a market cap of $16.68 billion, a price-to-earnings ratio of 15.07, a P/E/G ratio of 1.06 and a beta of 0.63. Molina Healthcare has a 1-year low of $262.32 and a 1-year high of $365.23.
Molina Healthcare (NYSE:MOH - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The company reported $6.08 earnings per share for the quarter, beating analysts' consensus estimates of $5.96 by $0.12. The company had revenue of $11.15 billion for the quarter, compared to the consensus estimate of $10.86 billion. Molina Healthcare had a return on equity of 28.13% and a net margin of 2.90%. The firm's quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.73 EPS. On average, equities research analysts anticipate that Molina Healthcare will post 24.4 EPS for the current year.
Molina Healthcare Company Profile
(
Get Free ReportMolina Healthcare, Inc provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments: Medicaid, Medicare, Marketplace, and Other. The company served in across 19 states. The company was founded in 1980 and is headquartered in Long Beach, California.
Further Reading

Before you consider Molina Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molina Healthcare wasn't on the list.
While Molina Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.